Dermatology Medical News about Melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians
Pharmacogenetics and genomics, 09/25/09

Boeckmann L et al. – The results indicate that either low or high host expression of MGMT, MLH1, and MSH2 may serve as a marker for reduced hematologic side effects of TMZ or DTIC, but not for treatment efficacy in melanoma. The genetic variant rs2303428 might serve as a predictive marker for hematologic side effects and treatment response.

<< Previous
The Nodal Location of Metastases in Melanoma Sentinel Lymph Nodes

Next >>
Rapid reversal of hyperpigmentation in pityriasis versicolor upon...